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Two human glucagon-like peptides, GLP-1 and GLP-2, which are coencoded with pancreatic glucagon in 
the preproglucagon gene, do not significantly inhibit [‘ZSI]monoiodoglucagon binding to rat liver and brain 
membranes and do not activate adenylate cyclase in liver plasma membranes. Nevertheless, GLP-1 and 
GLP-2 were each found to be potent stimulators of both rat hypothalamic and pituitary adenylate cyclase. 
Only 30-50 pM concentrations of each peptide elicited half-maximal adenylate cyclase stimulation. Our 
data suggest hat GLP-1 and GLP-2 may be neurotransmitters and/or neuroendocrine effecters, which 
would account for their high degree of sequence conservation through vertebrate volution. 
Glucagon-like peptide I Glucagon-like peptide 2 Glucagon CAMP Pituitar) Hypothalamus 
Liver plasma membrane 
1. INTRODUCTION 
Glucagon, a 29 amino acid peptide hormone is 
well-known for its important role in peripheral 
metabolic processes [l]. As is true for other pep- 
tide hormones, the synthesis of glucagon is 
thought to involve a larger precursor [2]. Although 
the pancreas is the most abundant source of 
glucagon, larger forms of glucagon have also been 
found in intestine, stomach, brain and salivary 
glands [3]. Inasmuch as pancreatic preproglucagon 
contains the sequences of several intestinal 
glucagon-containing polypeptides, it has been sug- 
gested that tissue-specific processing of a common 
precursor could generate an array of peptides [4]. 
amino acid sequences of the 3 glucagon precursors 
were found to be similar [6]. The 180 amino acid 
mammalian preproglucagon codes for a signal 
peptide, an amino-terminal glicentin-related pan- 
creatic polypeptide (GRPP), pancreatic glucagon, 
and two glucagon-like peptides called GLP-1 and 
GLP-2 arranged in tandem. Except for the signal 
peptide, the other coencoded peptides are flanked 
by dibasic residues which represent putative pro- 
cessing sites. The sequences of two non-allelic 
anglerfish pancreatic glucagon precursors have 
also been determined and their organization found 
to be similar except for the absence of GLP-2 [7]. 
Recently, the structures of hamster [4] and 
bovine [5] pancreatic preproglucagon were de- 
duced from the corresponding cloned cDNA. Fur- 
thermore, the structure of human preproglucagon 
was determined from a genomic sequence [a]. The 
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GLP-1 (37 amino acids) and GLP-2 (34 amino 
acids) are related but not identical to other 
members of the glucagon-secretin family of 
gastrointestinal hormones [4]. The two glucagon- 
like peptides have been described as ‘cryptic’ 
because their isolation and physiological properties 
had not been reported. The GLP-1 sequence 
possesses extensive homology between hamster 
and anglerfish and is identical in the 3 mammalian 
preproglucagons reported. Amino acid sequence 
homology of GLP-2 between human and hamster 
is 91.2% and between human and bovine it is 85%. 
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The high degree of sequence conservation of 
GLP-1 and GLP-2 has suggested that these pep- 
tides have important physiological functions 
[4,6,8]. This and the structural similarity to 
glucagon prompted us to investigate the ability of 
GLP-1 and GLP-2 to inhibit [1251]-monoiodoglu- 
cagon binding and to activate adenylate cyclase in 
liver plasma membranes. We have identified, 
localized and characterized glucagon receptors in 
rat brain and pituitary [9]. Therefore, we also 
examined the effect of the two peptides on rat 
hypothalamic and pituitary membranes. 
2. MATERIALS AND METHODS 
Chromatographically pure, synthetic human 
GLP-1 (36 amino acids with amidated C-terminal) 
and GLP-2 (34 residues) were purchased from 
Peninsula (Belmont, CA). Porcine glucagon (a gift 
from Eli Lilly and Co., Indianapolis, IN) was 
purified, iodinated using IODOGEN, and [“‘I]- 
monoiodoglucagon was purified as described in 
[ 101. Partially purified liver plasma membranes 
and hypothalamic as well as pituitary homogenates 
were prepared as described [9]. Competitive bind- 
ing and adenylate cyclase assays were performed as 
in [9]. 
3. RESULTS 
As shown in fig.1 (top), with membrane 
preparations from liver and brain, glucagon is able 
to displace [1251]-monoiodoglucan t half-maxi- 
mum concentrations of 1 and 5 nM, respectively. 
In neither preparation (4 separate assays) was 
GLP-1 or GLP-2 able to displace the labelled 
glucagon except to a minimal extent at much 
higher concentrations (> 1 PM) in liver. As shown 
in fig.1 (bottom), when GLP-1 and GLP-2 were 
assessed for their abilities to activate adenylate 
cyclase in liver membranes, neither peptide was 
able to activate cyclase to the extent or in the con- 
centration range at which glucagon itself is effec- 
tive. However, as shown in fig.2, with 
hypothalamus and pituitary membrane prepara- 
tions both GLP-1 and GLP-2 activate adenylate 
cyclase I-fold over basal activity in the presence of 
1 .O mM theophylline. The half-maximum concen- 
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Fig.1. Typical competition and dose response curves 
with glucagon and glucagon-like peptides. Top: 
displacement of [‘251]-monoiodoglucagon bou d to liver 
plasma membranes by (0) glucagon, (A) GLP-1 and 
( q ) GLP-2. Similar plots for hypothalamic and pituitary 
pooled homogenates with (0) glucagon, (A) GLP-1 and 
(w) GLP-2. Bottom: activation of liver plasma 
membrane adenylate cyclase by (0) glucagon, (0) 
GLP-1 and (0) GLP-2. Results are expressed as 
percentage of maximal activity attained by glucagon. 
Basal activity was 0.95 nmol CAMP formed per mg 
protein in 10 min. -3-fold activation over basal levels 
was seen with glucagon. SD of each point performed in 
triplicate was <5%. All assays were performed at least 
3 times. For glucagon kact = 3.7 nM. 
tration for activation is low, near 30-50 pM for 
GLP-1 and GLP-2, in contrast to 5 nM for 
glucagon itself [8]. As further seen in fig.2, at pep- 
tide concentrations greater than those which pro- 
duce maximum activation, cyclase activity falls 
rapidly to near basal levels for both GLP-1 and 
GLP-2 with both hypothalamic and pituitary 
membranes. Ki values are -0.8 nM for GLP-1 and 
-4 nM for GLP-2, concentrations very near those 
for half-maximum activation by glucagon. 
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Fig.2. Typical dose response curves for the activation of 
brain adenylate cyclase. Top: activation by GLP-1 in rat 
(of h~othalamic and (0) pituitary homogenates. 
Bottom: activation by (0. 0) GLP-2 and (=, 0) 
glucagon in (0, a) hypothalamic and (0, q ) pituitary 
homogenates. Basal activity was -0.5 and 0.15 nmol 
CAMP formed per mg wet wt of tissue for hypothalamic 
and pituitary homogenates, respectively. Activation over 
basal levels was -2-fold. Other details as in legend to 
fig. 1. 
4. DISCUSSION 
Our data clearly indicate that GLP-I and GLP-2 
do not interact with glucagon receptors in rat liver, 
pituitary or hypothalamic membranes at 
physiologically relevant concentrations (fig. I). 
However, the two glucagon-like peptides are very 
potent in activating adenylate cyclase in both rat 
hypothalamic as well as pituitary membranes at 
concentrations significantly lower (30-50 PM) 
than that seen for glucagon (5 nM). High dose in- 
hibition of adenylate cyclase seen with GLP-1 and 
GLP-2 has been reported earlier for a number of 
activators of adenylate cyclase including glucagon, 
secretin, &adrenergic agonists and prostaglandins 
[11,12]. 
There have been reports of the isolation of large 
molecular forms of glucagon from the CNS of rat 
[13] and dog [14,15]. In rat brain [13], two major 
polypeptides of molecular mass 8 and 12 kDa, and 
representing incompletely processed forms of 
preproglucagon were found. The sizes of these 
peptides and their selective glucagon-like im- 
munoreactivities were similar to intestinal 
glu~agon-related peptides [ 13,161. The 8-kDa pro- 
tein contains the amino acid sequences of GRPP 
and pancreatic glucagon. The size, biochemical 
and immunological properties of the l2-kDa pro- 
tein suggests that it encompasses GLP-1 in addi- 
tion to GRPP and pancreatic glucagon /4]. These 
studies provide indirect evidence for processing of 
preproglucagon to yield glucagon and giucagon- 
like peptides and suggest hat local synthesis of the 
peptides may occur in brain. 
Because GLP-1 and GLP-2 activate rat 
hypothalamic and pituitary adenylate cyclase at 
low concentrations and do not cross-react with 
glucagon receptors in both CNS and liver, it ap- 
pears that the two glucagon-like peptides have 
their own receptors and may well be novel 
neurotransmitters and/or neuromodulators. This 
may account for the highly conserved amino acid 
sequences of the two peptides. The physiologic role 
of GLP-1 and GLP-2 in the CNS remains 
enigmatic and requires further investigation. 
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